Eur J Cardiol. 1977 Dec;6(4):245-58.

Mexiletine in the management of ventricular dysrhythmias.

European journal of cardiology

N P Campbell, J F Pantridge, A A Adgey

PMID: 590296

Abstract

Mexiletine administered either intravenously or orally was found to be an effective antiarrhythmic agent. Unfortunately, important adverse effects occurred in approximately half of the patients. Adverse effects which appeared during oral therapy were dose related. Mexiletine controlled lignocaine-resistant ventricular dysrhythmias in more than half of the patients treated. Ventricular tachycardia and ventricular fibrillation occurred at plasma concentrations which were not significantly different from those associated with severe side-effects, suggesting that when mexiletine is used to control these major dysrhythmias the incidence of important side effects will be high.

Similar articles

Substances

• Propylamines
• Mexiletine
• Lidocaine

MeSH terms

• Administration, Oral
• Arrhythmias, Cardiac / drug therapy
• Dose-Response Relationship, Drug
• Drug Resistance
• Humans
• Injections, Intravenous
• Lidocaine / therapeutic use
• Mexiletine / administration & dosage
• Mexiletine / adverse effects
• Middle Aged
• Propylamines / adverse effects

Publication Types

• Journal Article